Blincyto®

Active substance Blinatumomab
Holder Amgen
Status Running
Indication adults with B-precursor acute lymphoblastic leukemia (ALL) in complete hematological remission defined as less than or equal to 5% blasts in the bone marrow after at least three intense chemotherapy blocks and presence of minimal residual disease (MRD) at a level ≥ 10-4
Public documents Approbation
Information for the patient
Informed consent
Last update 12/08/2019
Last updated on 29/11/2019